Key facts
- This page summarizes Dorothy G. Capers's Form 4 filing for Xylem Inc. (XYL).
- 7 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 06 Mar 2025, 16:11.
Dorothy G. Capers - 04 Mar 2025 Form 4 Insider Report for Xylem Inc. (XYL)
- Reporting relationship
- SVP & General Counsel
- Issuer ticker
- XYL
- Reported as of
- 04 Mar 2025
- Net transaction value
- +$389,878
- SEC form
- 4
- Accepted by SEC
- 06 Mar 2025, 16:11:05 UTC
- Prior SEC filing
- 04 Mar 2025
- Next SEC filing
- 02 May 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mike Nazario, by power of attorney for Dorothy G. Capers
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Dorothy G. Capers filed Form 4 for Xylem Inc. (XYL) on 06 Mar 2025.
Change
- Previous filing in this sequence was filed on 04 Mar 2025.
- Current net transaction value: +$389,878.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
XYL
transaction
Common Stock
Options Exercise
- Transaction value
- $682,628
- Shares
- +7,868
- Change %
- +98%
- Price
- $86.76
- Shares after
- 15,883
- Date
- 04 Mar 2025
- Ownership
- Direct
XYL
transaction
Common Stock
Options Exercise
- Transaction value
- $420,332
- Shares
- +4,158
- Change %
- +26%
- Price
- $101.09
- Shares after
- 20,041
- Date
- 04 Mar 2025
- Ownership
- Direct
XYL
transaction
Common Stock
Sale
- Transaction value
- $1,530,391
- Shares
- -12,026
- Change %
- -60%
- Price
- $127.26
- Shares after
- 8,015
- Date
- 04 Mar 2025
- Ownership
- Direct
- Footnotes
- F1
XYL
transaction
Common Stock
Award
- Transaction value
- $181,279
- Shares
- +1,398
- Change %
- +17%
- Price
- $129.67
- Shares after
- 9,413
- Date
- 05 Mar 2025
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
XYL
transaction
Derivative
Non-Qualified Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -4,158
- Change %
- -67%
- Price
- $0.000000
- Shares after
- 2,079
- Date
- 04 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,158
- Exercise price
- $101.09
- Footnotes
- F3
XYL
transaction
Derivative
Non-Qualified Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -7,868
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 04 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 7,868
- Exercise price
- $86.76
- Footnotes
- F4
XYL
transaction
Derivative
Non-Qualified Stock Options (Right to buy)
Award
- Transaction value
- $636,031
- Shares
- +4,905
- Change %
- Price
- $129.67
- Shares after
- 4,905
- Date
- 05 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,905
- Exercise price
- $129.67
- Footnotes
- F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
This price represents the weighted average price per share of common stock (each, a "Share") of Xylem Inc. (the "Issuer"). 12,026 Shares were executed at a range of prices from $125.25 to $125.35. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares sold at each price.
Footnote F2
Reflects an award of restricted stock units pursuant to the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016) that are scheduled to vest in one third increments on March 5, 2026, March 5, 2027 and March 5, 2028.
Footnote F3
The March 1, 2023 option grant vested 2,079 options on March 1, 2024, 2,079 options on March 1, 2025, and will vest 2,079 options on March 1, 2026.
Footnote F4
The March 1, 2022 option grant vested 2,623 options on March 1, 2023, 2,623 options on March 1, 2024, and 2,622 options on March 1, 2025.
Footnote F5
Reflects an award of non-qualified stock options pursuant to the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016) that are scheduled to vest in one-third increments on March 5, 2026, March 5, 2027 and March 5, 2028.